Drug intelligence / Profile preview

ethanol + bupivacaine

Development stage
Unknown
Lead developer
Pacira BioSciences
Modality
Small Molecules
Administration
Perineural Injection
01

Overview

Ethanol (ethyl alcohol) is a neurolytic agent used to provide long-term pain relief by inducing Wallerian degeneration of nerve fibers through protein denaturation and lipid extraction. In the clinical context of advanced knee osteoarthritis, it is administered via ultrasound-guided injection to the genicular nerves (superior lateral, superior medial, and inferior medial) to disrupt pain signaling. This specific intervention, studied by Tanta University, involves the use of ethanol in various concentrations (30%, 50%, and 70%) combined with the local anesthetic bupivacaine (0.25%) to mitigate the immediate pain associated with the neurolytic injection. The treatment is evaluated as an alternative to radiofrequency ablation for patients with chronic knee pain who are not candidates for or wish to delay total knee arthroplasty.

Other names
Alcohol 30% in 0.25% bupivacaineAlcohol 50% in 0.25% bupivacaineAlcohol 70% in 0.25% bupivacaineAlcoholic neurolysis of genicular nerveEthanol neurolysis
02

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)

Beyond the preview

Go deeper on ethanol + bupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethanol + bupivacaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call